HLK 1001
Alternative Names: HLK-1001Latest Information Update: 04 Oct 2024
Price :
$50 *
At a glance
- Originator HLK Pharmacin
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Breast cancer
Most Recent Events
- 04 Oct 2024 HLK 1001 is still in clinical trials for Breast cancer in an unknown location (HLK Pharmacin pipeline, October 2024)
- 04 Oct 2024 HLK has patent protection for its technology (HLK Pharmacin pipeline, October 2024)
- 04 Oct 2024 HLK Pharmacin plans to file an NDA application for Breast cancer in the Q3 2026 (HLK Pharmacin pipeline, October 2024)